S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:SAGE

Sage Therapeutics (SAGE) Stock Price, News & Analysis

$18.74
-0.30 (-1.58%)
(As of 03/28/2024 ET)
Today's Range
$18.51
$19.34
50-Day Range
$18.62
$26.71
52-Week Range
$16.51
$59.99
Volume
1.00 million shs
Average Volume
963,600 shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
118.8% Upside
$41.00 Price Target
Short Interest
Bearish
17.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.51
Upright™ Environmental Score
News Sentiment
0.84mentions of Sage Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.06) to ($4.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.77 out of 5 stars

Medical Sector

267th out of 938 stocks

Pharmaceutical Preparations Industry

119th out of 422 stocks

SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
Sage Therapeutics Inc.
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
SAGE Jan 2025 30.000 put
SAGE Therapeutics, Inc. Q4 Loss decreases, beats estimates
Sage Therapeutics Q4 2023 Earnings Preview
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAGE
Employees
487
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$294.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+118.8%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
17 Analysts

Profitability

Net Income
$-541,490,000.00
Net Margins
-626.32%
Pretax Margin
-626.33%

Debt

Sales & Book Value

Annual Sales
$86.46 million
Book Value
$13.32 per share

Miscellaneous

Free Float
56,801,000
Market Cap
$1.13 billion
Optionable
Optionable
Beta
0.87
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 61)
    President, CEO & Director
    Comp: $1.29M
  • Ms. Kimi E. Iguchi CPA (Age 62)
    CFO & Treasurer
    Comp: $665.37k
  • Ms. Anne Marie Cook Esq. (Age 62)
    Senior VP, General Counsel & Secretary
    Comp: $711.6k
  • Mr. Christopher Benecchi (Age 52)
    Chief Business Officer
    Comp: $703.76k
  • Dr. Laura Gault M.D.
    Ph.D., Chief Medical Officer
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Mr. Mike Quirk
    Chief Scientific Officer
  • Ashley Kaplowitz
    Director of Investor Relations
  • Ms. Erin E. Lanciani (Age 55)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Senior Vice President of R&D Strategy and Business Management

SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 14 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price target for 2024?

17 brokers have issued twelve-month target prices for Sage Therapeutics' shares. Their SAGE share price targets range from $20.00 to $294.00. On average, they predict the company's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 at the start of the year. Since then, SAGE stock has decreased by 13.5% and is now trading at $18.74.
View the best growth stocks for 2024 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.28) by $0.73. The biopharmaceutical company had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The firm's revenue was up 2621.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($2.47) earnings per share.

What ETFs hold Sage Therapeutics' stock?
What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Wellington Management Group LLP (10.08%), Vanguard Group Inc. (8.86%), Vanguard Group Inc. (8.85%), RTW Investments LP (8.66%), Palo Alto Investors LP (1.65%) and Dimensional Fund Advisors LP (1.61%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners